|本期目录/Table of Contents|

[1]任 静,朱仲玲,阎 昭.肾癌舒尼替尼耐药细胞株ACSUR的建立及其生物学特性研究[J].天津医科大学学报,2019,25(06):556-558+576.
 REN Jing,ZHU Zhong-ling,YAN Zhao.Establishment of sunitinib-resistant renal carcinoma cell line ACSUR and its biological characteristics[J].Journal of Tianjin Medical University,2019,25(06):556-558+576.
点击复制

肾癌舒尼替尼耐药细胞株ACSUR的建立及其生物学特性研究(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
25
期数:
2019年06期
页码:
556-558+576
栏目:
基础医学
出版日期:
2019-11-20

文章信息/Info

Title:
Establishment of sunitinib-resistant renal carcinoma cell line ACSUR and its biological characteristics
文章编号:
1006-8147(2019)06-0556-04
作者:
任 静朱仲玲阎 昭
(天津医科大学肿瘤医院临床药理研究室,国家肿瘤临床医学研究中心,天津市“肿瘤防治”重点实验室,天津市恶性肿瘤临床医学研究中心,天津 300060)
Author(s):
REN Jing ZHU Zhong-ling YAN Zhao
(Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China)
关键词:
肾癌舒尼替尼耐药
Keywords:
kidney cancer sunitinib drug resistance
分类号:
R737.11
DOI:
-
文献标志码:
A
摘要:
目的:探讨肾癌舒尼替尼耐药细胞株ACSUR的建立及其生物学特性。方法:以肾透明细胞癌ACHN细胞为亲本细胞,采用逐步递增药物浓度法诱导建立肾癌舒尼替尼耐药细胞株ACSUR。倒置显微镜下观察ACSUR细胞形态,MTT法检测细胞增殖,计算耐药指数。流式细胞仪检测细胞凋亡率,二维克隆法和划痕实验分别检测细胞的克隆形成能力和迁移能力。结果:ACSUR耐药指数为6.21,细胞多呈分散生长。与亲本细胞相比,ACSUR细胞凋亡率显著降低(P<0.05),而克隆形成及迁移能力明显增强(P<0.05)。结论:ACSUR具备耐药细胞的生物学特性,可为深入探索肾癌舒尼替尼耐药机制以及逆转耐药策略提供研究模型。
Abstract:
Objective: To produce sunitinib-resistant cell line ACSUR and explore its biological characteristics. Methods: ACHN renal cancer cells as parental cells were incubated with stepwise increasing concentration of sunitinib to produce ACSUR cells. Morphology of ACSUR cells was observed by an inverted microscope. Cell proliferation was measured by MTT assay and drug resistance index was calculated. Apoptosis rate was detected by flow cytometry. The abilities of colony formation and migration were determined by colony formation and wound healing assay respectively. Results: ACSUR resistance index was 6.21 and cells grew dispersely. Apoptosis rate was reduced significantly, while abilities of colony formation and migration were enhanced obviously in ACSUR cells(P<0.05). Conclusion: ACSUR cells possess the biological characteristics of resistant cells, which can provide a research model for exploring the mechanism of resistance to sunitinib and reversal of drug resistance.

参考文献/References:

[1] Qu L, Ding J, Chen C, et al.Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA[J].Cancer Cell, 2016,29(5): 653
[2] Capitanio U, Montorsi F. Renal cancer[J].Lancet, 2016,387(10021):894
[3] Tavazoie S F,Alarcón C,Oskarsson T,et al.Endogenous human microRNAs that suppress breast cancer metastasis[J].Nature, 2008, 451(7175): 147
[4] Molina A M, Lin X ,Korytowsky B, et al. Sunitinib objective response in metastatic renal cell carcinoma:analysis of 1059 patients treatedon clinical trials[J].Eur J Cancer, 2014, 50(2): 351
[5] Zhang L, Bhasin M, Schor-Bardach R, et al.Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible geneexpression[J].PLoS One, 2011, 6(4): e19144
[6] 曲乐, 王林辉, 刘冰, 等.肾癌舒尼替尼耐药细胞系及其构建方法[P]. 中国专利. CN104988122A. 2015-10-21
[7] Faivre S,Demetri G,Sargent W, et al. Molecular basis for sunitinib efficacy and future clinical development[J].Nat Rev Drug Discov,2007,6(9):734
[8] Takeuchi K, Ito F. EGF receptor in relation to tumor development:molecular basis of responsiveness of cancercells to EGFR-targeting tyrosine kinase inhibitors[J]. FEBS J, 2010, 277(2): 316
[9] Sato H, Yamamoto H, Sakaguchi M, et al.Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer[J]. Cancer Sci, 2018,109(10): 3183
[10] Randrup Hansen C, Grimm D, Bauer J, et al. Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma[J]. Int J Mol Sci, 2017, 18(2): Pii:E461.doi:10.3390/ijms18020461.
[11] Molina A M,Lin X,Korytowsky B, et al.Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials[J].Eur J Cancer, 2014,50(2): 351
[12] Shibasaki N,Yamasaki T,Kanno T, et al.Role of IL13RA2 in sunitinib resistance in clear cell renal cell carcinoma[J].PLoS One,2015,10(6): e0130980
[13] Park K,Lee J L,Park I, et al.Comparative efficacy of vascular endothelial growth factor(VEGF)tyrosine kinase inhibitor(TKI)and mammalian target of rapamycin(mTOR)inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI[J]. Med Oncol, 2012, 29(5): 3291
[14] Diaz R 1,Nguewa P A. Sunitinib reduces tumor hypoxia and angiogenesis,and radiosensitizes prostate cancer stem-like cells[J].Prostate,2015,75(11):1137
[15] Joosten S C, Hamming L. Resistance to sunitinib in renal cell carcinoma:from molecular mechanisms to predictivemarkers and future perspectives[J].Biochim Biophys Acta, 2015,1855(1):1

相似文献/References:

[1]秦振邦,王冬冬,杨 盼,等.肾粘液样小管状和梭形细胞癌的研究分析[J].天津医科大学学报,2017,23(01):43.

备注/Memo

备注/Memo:
基金项目 科技部“十三五”重大新药创制科技重大专项课题(2018ZX09201-015)
作者简介 任静(1995-),女,硕士在读,研究方向:肿瘤药理学;通信作者:阎昭,E-mail:yanzhaopaper@163.com。
更新日期/Last Update: 2020-01-20